Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Inhaled high molecular weight hyaluronan ameliorates respiratory failure in acute COPD exacerbation: a pilot study

Fig. 2

HMW-HA treatment reduces duration of NIPPV in AECOPD. a Kaplan–Meier curve of cumulative hours on NIPPV in intention-to-treat analysis. HMW-HA treated patients have significantly shorter time to liberation from NIPPV N = 20 for HMW-HA patients, N = 21 for placebo patients, intention-to-treat analysis. Patients who suffered an adverse event and were withdrawn from the study (N = 1 from each group), or withdrew consent (N = 2 for placebo, N = 1 for HMW-HA), were censored as “not liberated from NIPPV” for this analysis. One patient in the placebo group failed NIPPV, was orotracheally intubated and was censored as “not liberated from NIPPV” at 125 h (point of intubation). b Duration of NIPPV measured in hospital days. HMW-HA treated patients were liberated from NIPPV on average 1 day earlier compared to placebo-treated patients. N = 18 for both groups (2 patients in placebo group and one in HMW-HA group withdrew consent, and one patient each suffered an adverse event and was withdrawn from the study by the study physician). c Total length of stay. HMW-HA treated patients were discharged from the hospital on average 2 days earlier. N = 18 for both groups (explanation as in b)

Back to article page